Receives $US 2.8 million Investment

Receives $US 2.8 million Investment

Angels High Tech Investments Ltd.

Shares BiondVax Vision of Commercializing World's First Universal Flu Vaccine

Ziona, Israel - January 2, 2017

Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) is honored to announce that Angels High Tech Investments Ltd. has agreed to

invest NIS 10.9 million, approximately $US 2.83 million, in exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv

Stock Exchange (equivalent to 844,000 NASDAQ listed ADS) at the December 29, 2016 Tel Aviv closing market price. Following the

transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of the Company.

Investments is a company fully owned by Marius Nacht, Co-founder and Chairman of Check Point (NASDAQ: CHKP). Angels' healthcare

and life science portfolio is managed by aMoon Partners which is co-led by Dr. Yair Schindel and Marius Nacht.

Babecoff, BiondVax's Founder, President and CEO noted, "This investment is a vote of confidence in BiondVax and

its universal influenza vaccine candidate. We are now better positioned to complete our development plans and commercialize our

vaccine worldwide. This strategic partnership, together with clinical results and ongoing clinical trial collaborations in Europe

and the US (NIH) will enable us to proceed confidently into Phase 3 as planned."

Yair Schindel, aMoon Partners' Co-founder and Managing Partner commented, "We see great potential in BiondVax's

universal flu vaccine. We expect that this investment is the beginning of a strong partnership with BiondVax and we look forward

to doing our part in helping reduce the global morbidity and mortality caused by influenza viruses."

BiondVax Pharmaceuticals Ltd

is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season

protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes

a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system

for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.

further information, please contact:

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking

statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and

future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially

from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to,

the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results of the current Phase

2 & contemplated phase 3 trials, the adequacy of available cash resources to fund product development and commercialization and

the ability to raise capital when needed. The risks, uncertainties and assumptions referred to above are discussed in detail in

our reports filed with the Securities and Exchange Commission, including our annual report for the year ended December

31, 2015 on Form 20-F filed with the Securities and Exchange Commission on April 27, 2016. BiondVax Pharmaceuticals

Ltd. undertakes no obligation to update or revise any forward-looking statements.

Science Park, 14 Einstein Street, POB 4143, Ness Ziona 7414002, Israel

Tel: +972-(0)8-930-2529 www.BiondVax.com